Evidence report library
Browse health and science claims by evidence strength.
Search deHype reports by topic, grade, study type and clinical relevance. Each card gives the practical verdict first, then links to the full source-chain review.
Explore by topic
Top public report topics, ranked by current archive coverage.
Cancer
A guide to interpreting news and research about cancer, with evidence checks on headlines,…
7 reports
Dementia
Evidence checks about dementia headlines, Alzheimer’s claims, supplements, biomarkers, and…
7 reports
Diet and nutrition
Diet and nutrition headlines often exaggerate the strength of evidence, particularly when …
2 reports
Heart health
Evidence checks about cardiovascular headlines, cholesterol, blood pressure, stroke, stati…
1 report
Longevity
Explore evidence and critical reviews relating to ageing, biological age markers, and anti…
1 report
Mental health
Evidence checks about depression, anxiety, stress, psychedelics, apps, lifestyle intervent…
1 report
Latest evidence reports
Concise archive cards help readers decide whether to open the full source-chain report.
Evidence check: Copper drug clears toxic Alzheimer’s proteins and restores memory
Findings are promising but limited to laboratory mouse models; human benefit, safety, and effectiveness in Alzheimer’s are untested.
Animal/lab only Limited human evidence Hypothesis-generating only
Evidence check: Silica Nanoparticles Induce Ferroptosis, Reprogram Immunity in Prostate Cancer Models
The evidence is from mouse prostate cancer models only; while the approach is intriguing, there is no basis yet for clinical claims or implications for patients.
Animal/lab only No human evidence Hypothesis-generating only
Evidence check: Dementia: Joint pain supplement may speed progression
The evidence for glucosamine accelerating dementia is preliminary, indirect, and partly observational; findings require replication and do not justify clinical changes at this stage.
Early-stage only Observational human evidence Not clinically actionable
Evidence check: Science & Medicine: A pill that slows aging? San Antonio researchers are putting it to the test
The article is based on promising animal data and a description of an ongoing human trial, but does not present published human outcomes or direct clinical evidence for slowed ageing in people.
Preclinical/early-stage Limited human evidence Not clinically actionable
Evidence check: New psychedelic-like drugs could treat depression without making you trip
This is an appropriately enthusiastic report of early-stage drug discovery. It references robust lab work and novelty in chemical scaffolds, but there is no clinical, human, or meaningful disease-modifying evidence at this time. Human relevance remains hypothetical.
Early-stage only
Evidence check: A hidden map in your nose could explain how smell works
This article reports an important technical advance in understanding smell mapping in mice. There is no evidence that the organizational map or its manipulation directly restores smell or applies in humans at this time. The clinical impact is speculative.
Early-stage only No human evidence None
Evidence check: Your nose could detect Alzheimer’s years before symptoms begin
The research offers scientific insight into early immune changes and olfactory loss in Alzheimer’s, but the article’s diagnostic and therapeutic framing exceeds the current clinical evidence.
Over-framed Limited human evidence Clinically actionable
Evidence check: Scientists Discover Brain Pathway That May Slow Parkinson’s Disease – but Only in Women
The article describes preliminary findings from mouse models that cannot yet be applied to humans or guide clinical care.
Animal/lab only No human evidence Hypothesis-generating only
Evidence check: Scientists found a hidden Alzheimer’s trigger and shut it down
The research shows that targeting IDOL reduced amyloid plaques and improved certain neuronal features in animals, but there is no evidence yet for clinical effectiveness or safety in humans.
Preclinical only No human evidence
Evidence check: Why some brain cells are particularly vulnerable to multiple sclerosis
The Science News article closely reflects the findings of recent peer-reviewed research linking DNA repair deficits in CUX2 neurons to progression of MS, but the evidence is primarily from mouse models and comparative human tissue studies, not clinical trials or interventions. The clinical actionability for patients or providers is currently nil, while the potential for future targeting remains hypothetical.
Early-stage only Limited human evidence